Nocturia

Desmopressin is an established treatment for nocturia due to nocturnal polyuria. In Japan, low-dose formulations (25 and 50 μg) were approved only for men in 2019. However, age- and dose-specific prescribing patterns in real-world practice remain unclear.

Background and Objectives: Overactive bladder (OAB) is frequently associated with impaired quality of life and sleep disturbances, particularly in women with refractory symptoms. Non-invasive neuromodulation targeting autonomic regulation has emerged as a potential therapeutic approach.

To investigate the prevalence and factors associated with nocturia, defined as ≥ 2 times/night, among participants from the 2023 Japan Community Health Survey (JaCS 2023).

Using data from JaCS 2023, a nationwide online survey comprising 48 questionnaire items on lower urinary tract symptoms and daily life, 6210 participants aged 20-99 years were evaluated.

Nocturia is a common symptom among adults and is often associated with disrupted sleep and diminished quality of life. In many cases, it is driven by nocturnal polyuria, an imbalance in nighttime urine production.

To investigate the efficacy of desmopressin in older men with persistent nocturia due to nocturnal polyuria and then determine the independent factors affecting the efficacy of desmopressin.

Desmopressin 50 mg was administered for 12 weeks to 49 patients (76.

The gold standard treatment for nocturnal enuresis includes alarm treatment, although the exact mechanism behind its effectiveness remains uncertain. The aim of this study was to investigate whether the time to alarm activation progressively increases during treatment, and to explore whether alarm treatment causes a transition from enuresis episodes to nocturia.

Objective: Nocturia, defined as waking from sleep to void, is a frequent lower urinary tract symptom associated with impaired sleep quality and reduced quality of life. This study aimed to evaluate the prevalence of nocturia episodes and their impact on sleep disturbance and health-related quality of life.

The prevalence of nocturia-related sleep problems is higher in older people. This study investigated whether morning and evening light exposure is associated with the sleep problems related to objectively identified nocturnal urination in community-dwelling older adults.

To evaluate lifestyle modification achieved through a structured self-check sheet-based behavioral therapy program and its association with changes in nighttime frequency in patients with nocturia.

We analyzed 218 patients from 14 institutions aged ≥40 years who completed a 4-week behavioral therapy program.

Obstructive sleep apnea (OSA) is associated with lower urinary tract symptoms (LUTS), particularly nocturia, though mechanisms including hypoxia, intrathoracic pressure changes, and hormonal alterations.